"The comfort zone for parenteral commercialization" is how Hospira One 2 One labels itself on its website.
Within this comfort zone are custom commercialization services and contract manufacturing. So Hospira extends our initial list of bread-and-butter CMO functions on both ends.
In the custom commercialization house are product and specialized development services, international regulatory expertise and commercial services. The specialized development services span Phase II to launch and on to life-cycle management.
The contract manufacturing house, which has facilities around the world, provides such services as fill/finish, API-making, lyophilization, powder filling and syringe and cartridge filling. Also, the CMO has experience with biologics, cytotoxic drugs, betalactams and dispersed systems.
One 2 One has manufactured more than 25 large molecules and biologics for its clients, 15 of which are commercial products.
Hospira tied with Boehringer Ingelheim with a Q3 CP of 76%. One 2 One suffered in the CA category, however, ringing up 38% to B-I's 59%.